Skip to main
  1. Stocks
  2. Oruka Therapeutics Inc
  3. Forecast
ORKA

ORKA Stock Forecast & Price Target

ORKA Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Oruka Therapeutics is attractive because ORKA-001 has shown unusually strong and repeatable psoriasis efficacy, with 61% PASI 100 at 16 weeks in EVERLAST-B versus 63.5% in EVERLAST-A, while remaining clean on safety and supporting advancement of the 600mg dose into Phase 3. Its ~100-day half-life, more than 3x Skyrizi’s, creates a credible path to Q6M to Q12M maintenance dosing, which could materially reduce injection burden and improve commercial adoption in a market where efficacy still drives share. Financially, the company ended 3Q26 with $1.2 billion in cash and equivalents, guiding that this should fund operations through an ORKA-001 BLA filing, while ORKA-002 and ORKA-004 add pipeline breadth and option value.

Bears say

Oruka Therapeutics is a high-risk clinical-stage biotech with no commercial revenue, so its valuation depends heavily on successful development and eventual approval of ORKA-001 and ORKA-002. The investment case is weakened by meaningful regulatory uncertainty, including the possibility of regulators demanding additional or longer studies, changing approval standards, or limiting product labels in ways that reduce market traction. Financially, the company still needs to access capital markets to fund development and commercialization, and any clinical delays, trial failures across PsO, HS, or other indications, unexpected safety issues, or stronger competing longer-acting mAb therapies could materially pressure the stock.

ORKA has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Oruka Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

ORKA Analyst Forecast & Price Prediction

Get the latest ORKA stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ORKA

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Oruka Therapeutics Inc (ORKA) Forecast

Analysts have given ORKA a Strong Buy based on their latest research and market trends.

According to 9 analysts, ORKA has a Strong Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $128.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $128.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Oruka Therapeutics Inc (ORKA)


ORKA Analyst Forecast & Price Prediction

Get the latest ORKA stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ORKA

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ORKA stock data and trends